Martin Vodička

Dr. Martin Vodička

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TMTerezie Macková
Terezie Macková
MVMartin Vodička
Martin Vodička
Ondřej SlanařOndřej Slanař
Ondřej Slanař
MŠMartin Šíma
Martin Šíma
Aim: This study aimed to develop a population pharmacokinetic (PK) model of intravenous fluconazole and, using model-based simulations, propose initial dosing recommendations that optimize efficacy while limiting toxicity. Methods: Therapeutic drug monitoring data from 116 adult patients (183 serum concentrations) treated with intravenous fluconazole between 2022 and 2025 at a single center were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were applied to identify dosing strategies that maximize the probability of achieving the PK/PD efficacy target. Results: Estimated glomerular filtration rate (eGFR) was the strongest predictor of fluconazole clearance, and adjusted body weight (ABW) influenced the volume of distribution. For a patient with ABW of 75 kg and eGFR of 90 mL/min, the estimated volume of distribution and clearance were 41.6 L and 0.81 L/h, respectively. An eGFR-based dosing nomogram was developed, and simulations demonstrated that this approach outperformed standard dosing regimens in achieving the PK/PD target. Conclusions: These findings suggest an initial loading dose (2.8 times the maintenance dose) followed by individualized, eGFR-guided maintenance dosing to enhance the safety and efficacy of intravenous fluconazole therapy; however, prospective clinical validation is required before routine clinical implementation.

17 September 2026 in Annals of Medicine
Verified
Journal Article
Open access
JKJosef Klhůfek
Josef Klhůfek
MVMartin Vodička
Martin Vodička
MFMartin Fajkus
Martin Fajkus
IRIlja Ryšavý
Ilja Ryšavý
VKVladimír Kojecký
Vladimír Kojecký
TŠTomáš Šálek
Tomáš Šálek
1. Spironolactone, a synthetic steroidal antagonist of the mineralocorticoid receptor, was first synthesized in 1957 [1]. Since its introduction into clinical practice, it has become an essential t...